Are 's (NYSE: PFE) best days behind it? If the stock's critics are to be believed, the answer is an emphatic "yes, obviously," with issues like its recent stint of unprofitability and a beaten-down top line being the primary pieces of supporting evidence.

But even the best companies can sometimes have a few quarters of difficulty, and investors should hesitate before counting this stock out. Let's analyze the arguments on each side and reach an actionable conclusion.

What does it even mean for someone to say that it's too late to buy shares of one of the world's biggest and best-known pharmaceutical stocks? Perhaps Pfizer's detractors believe that the majority of the growth opportunity is in the past. One quick look at this chart indicates that they might be on to something:

Continue reading

Source Fool.com